Recommendation – Talk Bio

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, HHS, Immunization, Policy, public health medicine (field), Recommendation, Robert F. Kennedy, Vaccines

ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy

CDC Recommends Pneumococcal Vaccination for Adults 50 Years and Older

6 months ago talkbio0Tagged Administration of vaccine product containing only Streptococcus pneumoniae antigen (procedure), Adult, Centers for Disease Control and Prevention (U.S.), older, pneumococcal disease prevention, Recommendation, respiratory season

Pneumococcal vaccination, CDC recommendations, adults 50 and older, pneumococcal disease prevention, winter respiratory season.

Impact of New CDC Guidelines on RSV Vaccine Makers

9 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Guidelines, Guillain-Barre Syndrome, Maker (occupation), Moderna, Pfizer, Recommendation, Respiratory Syncytial Virus Vaccines, SmithKline Beecham, Vaccination, Vaccines

RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

CDC Expands RSV Vaccine Recommendations for Adults 75 and Older

10 months ago talkbio0Tagged Adult, Centers for Disease Control and Prevention (U.S.), older, public health medicine (field), Recommendation, Respiratory Syncytial Virus Vaccines, Vaccination

RSV vaccine, CDC, adults 75 and older, vaccination recommendations, public health

Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports

1 year ago talkbio0Tagged Active shortages, Adderall, American Society of Health-System Pharmacists, Antineoplastic Agents, ASHP, Attention deficit hyperactivity disorder, Drug Enforcement Administration, Drug shortages, Drug supply chains, Generic sterile injectable medications, Policy, Recommendation, Record-high

Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations

Brukinsa Broadens Horizons: FDA Clears Follicular Lymphoma Combination Therapy

1 year ago talkbio0Tagged Accelerated, Approved, broadest label, Brukinsa, BTK Inhibitor, CHMP, Chronic lymphoma, Combined Modality Therapy, Lymphoma, Follicular, obinutuzumab, Oregon (geographic location), Overall response rate, Phase 2 Clinical Trials, Phase II ROSEWOOD trial, Recommendation, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Relapsing course, Rosewood, United States Food and Drug Administration

Brukinsa, Follicular lymphoma, FDA approval, BTK inhibitor, BTK inhibitor, Broadest label, Relapsed or refractory follicular lymphoma, ROSEWOOD Phase II study, CHMP positive opinion, Obinutuzumab combination therapy, Accelerated approval, Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma, Chronic lymphoma, CHMP recommendation, Phase II ROSEWOOD trial, Overall response rate (OR